- Shared Resources
- Mouse Cardiovascular Phenotyping Core
The Mouse Cardiovascular Physiology Core provides services to assess cardiovascular function in mouse models and to provide validated surgical models of heart and vascular disease in mice to assess genetic or therapeutic interventions. We will work with investigators to design and implement the study along with any associated grant applications, animal protocol submissions and manuscript preparation. While the central focus of the facility is cardiovascular research, the techniques employed are often useful to investigators in other fields. Our Core staff will work with you to assess your needs and provide the necessary technical training and scientific assistance in animal protocol preparation. The Core runs on a fee-for-service model. Accordingly, investigators will be responsible for the costs incurred for their projects and prior animal protocol approval by Penn IACUC.
Mouse Cardiovascular Phenotyping Core
Swapnil V. Shewale, M.S., Ph.D., Mouse Echocardiographer
Smilow TRC 11-122
Kendra McDaid, Cardiac Surgeon
Smilow TRC 11-122
Marielle Scherrer-Crosbie, M.D., Ph.D., Faculty Core Advisor for Echocardiography
South Pavilion 11-131
Daniel P. Kelly, M.D., Faculty Core Advisor for Cardiac Surgery and Physiology
Smilow TRC 11-122
Cost is per mouse/per time point. Non-invasive single transthoracic cardiac ultrasound exam performed under Avertin (tribromoethanol)-induced anesthesia.
Users can consider A for screening mice for homogenous decreases in function /hypertrophy (e.g. sepsis, etc.). Consider D in mice with regional wall motion abnormalities. Note that M Mode parameters do not accurately represent LV structure and function.
- SCREENING ECHO
M-Mode images acquired to obtain the following: HR, IVSd (mm), LVIDd (mm), LVPWd (mm), IVSs (mm), LVIDs (mm), LVPWs (mm), LV FS (%), LVM and RWT.
- SCREENING ECHO +
Acquisition and analysis of M-Mode as above and assessment of diastolic function using acquisition and analysis of mitral inflow Doppler and mitral annulus tissue velocities to obtain the following: E, A, E/A, S’, E’, A’, E/E’, IVCT,IVRT, ET and Tei Index/MPI.
- TAC ECHO
Screening echo plus aortic gradient.
- MI ECHO
Will include 2D long axis imaging and analysis to obtain EDV (µL), ESV (µL) and EF (%) and serial short axis imaging for regional wall motion.
- TAC+ MI (Heart Failure) ECHO
MI echo plus aortic gradient and analysis.
- LV STRAIN ANALYSIS
- TRANSVERSE AORTIC CONSTRICTION (TAC)- Compensated LV Hypertrophy Model
Operative placement of constriction on transverse aorta that results in left ventricular hypertrophy with normal systolic function in timeframe of 1-4 weeks. Timing of endpoint determined by scientific question. Recommend M-mode echo with gradient at endpoint.
- MYOCARDIAL INFARCTION (MI)
Operative placement of a permanent occlusion around the left anterior descending artery of the mouse heart. Includes recording mouse weight. Size of MI can be customized but is typically sufficient size to impact LV function. Recommended Complete 2D echo and collection of endpoints at 1-2 weeks post-surgery.
- OPEN CHEST ISCHEMIA REPERFUSION INJURY (OCIR)
Operative placement of an occluder around the left anterior descending artery for 30-45mins of occlusion followed by reperfusion for typically 24hrs. Vital dye staining will also be performed which involves euthanasia and placement of infusion line in aorta, and ligation of innominate artery, carotid artery and left subclavian artery. Heart will then be perfused with tetrazolium chloride and Evans Blue, with analysis to determine infarcted area and “area at risk”.
- COMBINED TRANSVERSE AORTIC CONSTRICTION (TAC)/MYOCARDIAL INFARCTION (MI) – Heart Failure (HF) Model
Operative placement of constriction on the transverse aorta combined with a small myocardial infarction caused by permanent ligation of the distal third of the left anterior descending artery. Heart Failure (global LV dilatation and remodeling) will typically progress over a 4 week period. Recommend Complete 2D echo at endpoint.
- PRE-WEANING AORTIC BANDING (PWAB)
Operative placement of constriction on the ascending aorta at 3 weeks of age. PWAB results in left ventricular hypertrophy. Recommended 8-10 week post surgery echo with systolic and diastolic assessment.
- INJECTIONS OF PHARMACOLOGICAL AGENTS
Defined by P.I. and approved by Core staff during any of above studies.
- JUGULAR CATHETERIZATION (for drug infusion)
- ALZET PUMP IMPLANTATION
- ORGAN HARVEST
- HEMODYNAMICS I
Millar catheter placement, in carotid/aorta and recording of arterial or aortic pressures only.
- HEMODYNAMICS II
Millar catheter placement in left or right ventricle, and derivation of ventricular peak pressures, ventricular end-diastolic pressure, +/- dP/dt, and tau.
- HEMODYNAMICS III
Millar catheter placement into left ventricle and recording of LV measurements as in “Hemodynamics II” during pharmacological intervention (Dobutamine Challenge).
- HEMODYNAMICS IV
Millar catheter placement into left ventricle, Pressure-Volume loop recording including all measurements of “Hemodynamics II”.
- JUGULAR CATHETERIZATION
Includes surgery and infusion catheter placement in jugular vein (for drug or other infusions).
- ORGAN HARVEST
Includes collection of tissues or bodily fluids in either liquid nitrogen or formalin.
Other services are available upon request. Please email Kendra.McDaid@pennmedicine.upenn.edu.